Recent advances in the management of hepatocellular carcinoma

키워드

참고문헌 (68)

1. Lee YT, "The mortality and overall survival trends of primary liver cancer in the United States", J Natl Cancer Inst, 113, pp.1531~1541 (2021)
2. Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
3. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
4. Lee YT, "State-Level HCC incidence and association with obesity and physical activity in the United States", Hepatology, 74, pp.1384~1394 (2021)
5. "CT/MRI LI-RADS® v2017 CORE"[URL]
6. Yang JD, "New advances in the diagnosis and management of hepatocellular carcinoma", BMJ, 371, pp.m3544~ (2020)
7. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
8. Llovet JM, "Prognosis of hepatocellular carcinoma : the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
9. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
10. Llovet JM, "Natural history of untreated nonsurgical hepatocellular carcinoma : rationale for the design and evaluation of therapeutic trials", Hepatology, 29, pp.62~67 (1999)
11. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
12. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
13. Finn RS, "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
14. Abou-Alfa GK, "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", NEJM Evid, 1, pp.EVIDoa2100070~ (2022)
15. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
16. Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
17. Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebocontrolled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
18. Sangro B, "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C", J Hepatol, 59, pp.81~88 (2013)
19. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
20. Zhu AX, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a non-randomised, open-label phase 2 trial", Lancet Oncol, 19, pp.940~952 (2018)
21. Yau T, "Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459) : a randomised, multicentre, open-label, phase 3 trial", Lancet Oncol, 23, pp.77~90 (2022)
22. Finn RS, "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : A randomized, double-blind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
23. Qin S, "Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma : A randomized, double-blind, phase III trial", J Clin Oncol, 41, pp.1434~1443 (2023)
24. Finn RS, "IMbrave150 : updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab+ bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma", J Clin Oncol, 39(3 suppl), pp.267~ (2021)
25. Fulgenzi CAM, "Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice : Results of the AB-real study", Eur J Cancer, 175, pp.204~213 (2022)
26. Yau T, "Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib : The CheckMate 040 randomized clinical trial", JAMA Oncol, 6, pp.e204564~ (2020)
27. Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
28. Shigeta K, "Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma", Hepatology, 71, pp.1247~1261 (2020)
29. Wallin JJ, "Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma", Nat Commun, 7, pp.12624~ (2016)
30. Socinski MA, "Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC", N Engl J Med, 378, pp.2288~2301 (2018)
31. Ziogas AC, "VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2", Int J Cancer, 130, pp.857~864 (2012)
32. Motz GT, "The parallel lives of angiogenesis and immunosuppression : cancer and other tales", Nat Rev Immunol, 11, pp.702~711 (2011)
33. Yang J, "Targeting VEGF", VEGFR to modulate antitumor immunity, 2018, pp.9, 978~
34. Kandalaft LE, "Angiogenesis and the tumor vasculature as antitumor immune modulators : the role of vascular endothelial growth factor and endothelin", Curr Top Microbiol Immunol, 344, pp.129~148 (2011)
35. Gabrilovich DI, "Coordinated regulation of myeloid cells by tumours", Nat Rev Immunol, 12, pp.253~268 (2012)
36. Motz GT, "Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors", Nat Med, 20, pp.607~615 (2014)
37. Finn RS, "LBA34Primary results from the phase III LEAP-002 study : Lenvatinib plus pembrolizumab versus lenvatinib as first-line(1L)therapy for advanced hepatocellular carcinoma(aHCC)", Ann Oncol, 33(Suppl 7), pp.S1401~ (2022)
38. Kelley RK, "Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312) : a multicentre, openlabel, randomised, phase 3 trial", Lancet Oncol, 23, pp.995~1008 (2022)
39. Ren Z, "Sintilimab plus a bevacizumab biosimilar(IBI305)versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32) : a randomised, openlabel, phase 2-3 study", Lancet Oncol, 22, pp.977~990 (2021)
40. Qin S, "LBA35 Camrelizumab(C)plus rivoceranib(R)vs. sorafenib(S)as first-line therapy for unresectable hepatocellular carcinoma(uHCC) : A randomized, phase III trial", Ann Oncol, 33(Suppl 7), pp.S1401~S1402 (2022)
41. Colton M, "Reprogramming the tumour microenvironment by radiotherapy : implications for radiotherapy and immunotherapy combinations", Radiat Oncol, 15, pp.254~ (2020)
42. Yu J, "Liver metastasis restrains immunotherapy efficacy via macrophagemediated T cell elimination", Nat Med, 27, pp.152~164 (2021)
43. Deng L, "Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice", J Clin Invest, 124, pp.687~695 (2014)
44. Young KH, "Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy", PLoS One, 11, pp.e0157164~ (2016)
45. Wehrenberg-Klee E, "Y-90radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma", Cardiovasc Intervent Radiol, 41, pp.1799~1802 (2018)
46. Chiang CL, "Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma : A potential synergistic treatment strategy", Front Oncol, 9, pp.1157~ (2019)
47. Chiang CL, "Combined stereotactic body radiotherapy and immunotherapy versus transarterial chemoembolization in locally advanced hepatocellular carcinoma : A propensity score matching analysis", Front Oncol, 11, pp.798832~ (2021)
48. Juloori A, "Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced", unresectable hepatocellular carcinoma, 2023, pp.115, 202~213
49. Ali MY, "Activation of dendritic cells by local ablation of hepatocellular carcinoma", J Hepatol, 43, pp.817~822 (2005)
50. Fei Q, "High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer", Cell Death Dis, 11, pp.589~ (2020)
51. Wu H, "Palliative radiofrequency ablation accelerates the residual tumor progression through increasing tumor-infiltrating MDSCs and reducing T-Cell-mediated anti-tumor immune responses in animal model", Front Oncol, 10, pp.1308~ (2020)
52. Shi L, "PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor", Clin Cancer Res, 22, pp.1173~1184 (2016)
53. Duffy AG, "Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma", J Hepatol, 66, pp.545~551 (2017)
54. Zhang JX, "Safety and efficacy of transarterial chemoembolization and immune checkpoint inhibition with camrelizumab for treatment of unresectable hepatocellular carcinoma", J Hepatocell Carcinoma, 9, pp.265~272 (2022)
55. Chew V, "Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma", Gut, 68, pp.335~346 (2019)
56. Iyer RV, "A phase II study of atezolizumab(ATEZO)and bevacizumab(BEV)in combination with Y90 TARE in patients(pts)with hepatocellular carcinoma(HCC) : Y90+", -BEAT, 2023, pp.41(4 Suppl), TPS629~
57. Peng Z, "Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma : A phase III, randomized clinical trial(LAUNCH)", J Clin Oncol, 41, pp.117~127 (2023)
58. Öcal O, "Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib", Eur J Nucl Med Mol Imaging, 49, pp.4716~4726 (2022)
59. Kudo M, "Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma : TACTICS trial", Gut, 69, pp.1492~1501 (2020)
60. Ho WJ, "Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity", Nat Cancer, 2, pp.891~903 (2021)
61. Zhu A, "Abstract CT284 : Phase 3 KEYNOTE-937 : Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation", Cancer Res, 80(16 Suppl), pp.CT284~ (2020)
62. Exposito MJ, "CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation", Ann Oncol, 29, pp.viii267~viii268 (2018)
63. Hack SP, "IMbrave 050 : a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation", Future Oncol, 16, pp.975~989 (2020)
64. Chow P, "Abstract CT003 : IMbrave050 : Phase 3 study of adjuvant atezolizumab+bevacizumab versus active surveillance in patients with hepatocellular carcinoma(HCC)at high risk of disease recurrence following resection or ablation", Cancer Res, 83(8_Suppl), pp.CT003~ (2023)
65. Franses JW, "Neoadjuvant approaches in hepatocellular carcinoma : There’s no time like the present", Clin Cancer Res, 28, pp.2738~2743 (2022)
66. D’Alessio A, "Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis : A real-world study", Hepatology, 76, pp.1000~1012 (2022)
67. Iavarone M, "Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation", Am J Transplant, 19, pp.3176~3184 (2019)
68. DeLeon TT, "Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation : the Mayo Clinic experience", J Gastrointest Oncol, 9, pp.1054~1062 (2018)

관련 논문AI추천